CN103074446A - 一种人类免疫缺陷病毒核酸检测试剂盒 - Google Patents
一种人类免疫缺陷病毒核酸检测试剂盒 Download PDFInfo
- Publication number
- CN103074446A CN103074446A CN2013100090323A CN201310009032A CN103074446A CN 103074446 A CN103074446 A CN 103074446A CN 2013100090323 A CN2013100090323 A CN 2013100090323A CN 201310009032 A CN201310009032 A CN 201310009032A CN 103074446 A CN103074446 A CN 103074446A
- Authority
- CN
- China
- Prior art keywords
- primer
- probe
- pol
- ltr
- gag
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 241000725303 Human immunodeficiency virus Species 0.000 title claims abstract description 46
- 238000001514 detection method Methods 0.000 title claims abstract description 46
- 108020004707 nucleic acids Proteins 0.000 title claims abstract description 23
- 102000039446 nucleic acids Human genes 0.000 title claims abstract description 23
- 150000007523 nucleic acids Chemical class 0.000 title claims abstract description 23
- 239000000523 sample Substances 0.000 claims abstract description 74
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 30
- 238000006243 chemical reaction Methods 0.000 claims abstract description 24
- 101100025355 Oryza sativa subsp. japonica MYB4 gene Proteins 0.000 claims abstract description 19
- 101150046160 POL1 gene Proteins 0.000 claims abstract description 19
- 101100117436 Thermus aquaticus polA gene Proteins 0.000 claims abstract description 19
- 101100224481 Dictyostelium discoideum pole gene Proteins 0.000 claims abstract description 13
- 101150110488 POL2 gene Proteins 0.000 claims abstract description 13
- 101000690429 Panax ginseng Floral homeotic protein AGAMOUS Proteins 0.000 claims abstract description 13
- 238000012360 testing method Methods 0.000 claims description 37
- 238000011144 upstream manufacturing Methods 0.000 claims description 23
- 239000011324 bead Substances 0.000 claims description 16
- 239000000284 extract Substances 0.000 claims description 16
- 230000005291 magnetic effect Effects 0.000 claims description 16
- 101150088264 pol gene Proteins 0.000 claims description 6
- 238000003757 reverse transcription PCR Methods 0.000 claims description 6
- DPDMMXDBJGCCQC-UHFFFAOYSA-N [Na].[Cl] Chemical compound [Na].[Cl] DPDMMXDBJGCCQC-UHFFFAOYSA-N 0.000 claims description 4
- 108700004026 gag Genes Proteins 0.000 claims description 4
- 101150098622 gag gene Proteins 0.000 claims description 4
- 239000012745 toughening agent Substances 0.000 claims description 4
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 claims description 4
- 229940071125 manganese acetate Drugs 0.000 claims description 3
- UOGMEBQRZBEZQT-UHFFFAOYSA-L manganese(2+);diacetate Chemical compound [Mn+2].CC([O-])=O.CC([O-])=O UOGMEBQRZBEZQT-UHFFFAOYSA-L 0.000 claims description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 claims description 2
- 239000004141 Sodium laurylsulphate Substances 0.000 claims description 2
- DBLXOVFQHHSKRC-UHFFFAOYSA-N ethanesulfonic acid;2-piperazin-1-ylethanol Chemical compound CCS(O)(=O)=O.OCCN1CCNCC1 DBLXOVFQHHSKRC-UHFFFAOYSA-N 0.000 claims description 2
- ZJYYHGLJYGJLLN-UHFFFAOYSA-N guanidinium thiocyanate Chemical compound SC#N.NC(N)=N ZJYYHGLJYGJLLN-UHFFFAOYSA-N 0.000 claims description 2
- 239000002480 mineral oil Substances 0.000 claims description 2
- 235000010446 mineral oil Nutrition 0.000 claims description 2
- 235000019333 sodium laurylsulphate Nutrition 0.000 claims description 2
- 241000713772 Human immunodeficiency virus 1 Species 0.000 abstract description 21
- 230000035945 sensitivity Effects 0.000 abstract description 9
- 238000002360 preparation method Methods 0.000 abstract description 4
- 238000011002 quantification Methods 0.000 abstract 2
- 238000000034 method Methods 0.000 description 27
- 239000000243 solution Substances 0.000 description 25
- 241000700605 Viruses Species 0.000 description 20
- 208000030507 AIDS Diseases 0.000 description 15
- 230000003321 amplification Effects 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 238000003199 nucleic acid amplification method Methods 0.000 description 9
- 239000000427 antigen Substances 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 8
- 238000012408 PCR amplification Methods 0.000 description 7
- 230000008859 change Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 208000011580 syndromic disease Diseases 0.000 description 6
- 238000013461 design Methods 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 238000002156 mixing Methods 0.000 description 5
- 239000013612 plasmid Substances 0.000 description 5
- 238000003753 real-time PCR Methods 0.000 description 5
- 239000012925 reference material Substances 0.000 description 5
- 230000003612 virological effect Effects 0.000 description 5
- 238000002965 ELISA Methods 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- 238000002123 RNA extraction Methods 0.000 description 4
- 230000008901 benefit Effects 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 108091033319 polynucleotide Proteins 0.000 description 4
- 102000040430 polynucleotide Human genes 0.000 description 4
- 239000002157 polynucleotide Substances 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004445 quantitative analysis Methods 0.000 description 4
- 108020004414 DNA Proteins 0.000 description 3
- 238000010521 absorption reaction Methods 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 230000009514 concussion Effects 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 230000005298 paramagnetic effect Effects 0.000 description 3
- 239000002245 particle Substances 0.000 description 3
- 239000013641 positive control Substances 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000005406 washing Methods 0.000 description 3
- 102000016928 DNA-directed DNA polymerase Human genes 0.000 description 2
- 108010014303 DNA-directed DNA polymerase Proteins 0.000 description 2
- 208000037357 HIV infectious disease Diseases 0.000 description 2
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 2
- 238000011529 RT qPCR Methods 0.000 description 2
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000005336 cracking Methods 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 108700004025 env Genes Proteins 0.000 description 2
- 101150030339 env gene Proteins 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 2
- 210000005087 mononuclear cell Anatomy 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 238000002205 phenol-chloroform extraction Methods 0.000 description 2
- 108700004029 pol Genes Proteins 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000010791 quenching Methods 0.000 description 2
- 230000000171 quenching effect Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000001262 western blot Methods 0.000 description 2
- UPLPHRJJTCUQAY-WIRWPRASSA-N 2,3-thioepoxy madol Chemical compound C([C@@H]1CC2)[C@@H]3S[C@@H]3C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@](C)(O)[C@@]2(C)CC1 UPLPHRJJTCUQAY-WIRWPRASSA-N 0.000 description 1
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108010044091 Globulins Proteins 0.000 description 1
- 102000006395 Globulins Human genes 0.000 description 1
- 241000711549 Hepacivirus C Species 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108091028043 Nucleic acid sequence Proteins 0.000 description 1
- 208000001388 Opportunistic Infections Diseases 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 241000220317 Rosa Species 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 101800001690 Transmembrane protein gp41 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000009849 deactivation Effects 0.000 description 1
- 239000005549 deoxyribonucleoside Substances 0.000 description 1
- 230000010460 detection of virus Effects 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 238000013399 early diagnosis Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011010 flushing procedure Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000013467 fragmentation Methods 0.000 description 1
- 238000006062 fragmentation reaction Methods 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000002101 lytic effect Effects 0.000 description 1
- 239000011572 manganese Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 108700004028 nef Genes Proteins 0.000 description 1
- 101150023385 nef gene Proteins 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 238000011155 quantitative monitoring Methods 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 239000013558 reference substance Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 108700004030 rev Genes Proteins 0.000 description 1
- 101150098213 rev gene Proteins 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000005477 standard model Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 108700004027 tat Genes Proteins 0.000 description 1
- 101150098170 tat gene Proteins 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
Abstract
Description
Claims (9)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310009032.3A CN103074446B (zh) | 2013-01-10 | 2013-01-10 | 一种人类免疫缺陷病毒核酸检测试剂盒 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201310009032.3A CN103074446B (zh) | 2013-01-10 | 2013-01-10 | 一种人类免疫缺陷病毒核酸检测试剂盒 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103074446A true CN103074446A (zh) | 2013-05-01 |
CN103074446B CN103074446B (zh) | 2014-04-09 |
Family
ID=48151139
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201310009032.3A Active CN103074446B (zh) | 2013-01-10 | 2013-01-10 | 一种人类免疫缺陷病毒核酸检测试剂盒 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103074446B (zh) |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103667534A (zh) * | 2013-12-12 | 2014-03-26 | 东北制药集团辽宁生物医药有限公司 | 一种艾滋病(hiv-1)高精确核酸定量检测的方法及其试剂盒 |
CN104711370A (zh) * | 2015-01-09 | 2015-06-17 | 湖南圣湘生物科技有限公司 | 一种埃博拉病毒分型荧光pcr检测试剂盒 |
CN104846116A (zh) * | 2015-04-14 | 2015-08-19 | 广州海力特生物科技有限公司 | 检测人类免疫缺陷病毒1型的pcr引物组、探针及其试剂盒和检测方法 |
WO2015192327A1 (zh) * | 2014-06-17 | 2015-12-23 | 深圳迈瑞生物医疗电子股份有限公司 | 试剂盒及其制作方法 |
CN105567867A (zh) * | 2014-10-11 | 2016-05-11 | 上海仁度生物科技有限公司 | 人类免疫缺陷病毒1型实时荧光核酸恒温扩增检测试剂盒 |
CN106119413A (zh) * | 2016-07-01 | 2016-11-16 | 浙江省疾病预防控制中心 | 一种艾滋病病毒多重荧光pcr检测试剂盒及检测方法 |
CN107090521A (zh) * | 2017-05-09 | 2017-08-25 | 广州海力特生物科技有限公司 | 一种人类免疫缺陷病毒ⅰ型总核酸hiv‑1 tna的试剂盒及其应用 |
CN107326102A (zh) * | 2017-08-01 | 2017-11-07 | 广西中医药大学附属瑞康医院(广西中西医结合医院) | 一种艾滋病试剂盒 |
CN107523648A (zh) * | 2017-07-26 | 2017-12-29 | 李桂秋 | 一种人类免疫缺陷病毒核酸定量检测试剂盒 |
CN108998570A (zh) * | 2018-08-14 | 2018-12-14 | 首都医科大学附属北京佑安医院 | 可覆盖多亚型的hiv-1总dna定量检测引物对、探针及检测试剂盒 |
CN109136395A (zh) * | 2018-08-27 | 2019-01-04 | 郑州安图生物工程股份有限公司 | 一种b族链球菌核酸检测试剂盒 |
CN109777891A (zh) * | 2019-03-19 | 2019-05-21 | 上海邦耀生物科技有限公司 | 一种检测gag基因的引物对和荧光探针的组合和检测方法 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20180202009A1 (en) * | 2014-10-31 | 2018-07-19 | Keio University | Hiv pathology marker and examination method |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1940090A (zh) * | 2006-10-09 | 2007-04-04 | 卫生部北京医院 | 快速检测hiv病毒的核苷酸序列、方法及体外诊断试剂盒 |
CN102154510A (zh) * | 2011-02-25 | 2011-08-17 | 湖南圣湘生物科技有限公司 | 丙型肝炎病毒核酸定量检测试剂盒 |
-
2013
- 2013-01-10 CN CN201310009032.3A patent/CN103074446B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1940090A (zh) * | 2006-10-09 | 2007-04-04 | 卫生部北京医院 | 快速检测hiv病毒的核苷酸序列、方法及体外诊断试剂盒 |
CN102154510A (zh) * | 2011-02-25 | 2011-08-17 | 湖南圣湘生物科技有限公司 | 丙型肝炎病毒核酸定量检测试剂盒 |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103667534A (zh) * | 2013-12-12 | 2014-03-26 | 东北制药集团辽宁生物医药有限公司 | 一种艾滋病(hiv-1)高精确核酸定量检测的方法及其试剂盒 |
CN105940302B (zh) * | 2014-06-17 | 2018-10-09 | 深圳迈瑞生物医疗电子股份有限公司 | 试剂盒及其制作方法 |
WO2015192327A1 (zh) * | 2014-06-17 | 2015-12-23 | 深圳迈瑞生物医疗电子股份有限公司 | 试剂盒及其制作方法 |
CN105940302A (zh) * | 2014-06-17 | 2016-09-14 | 深圳迈瑞生物医疗电子股份有限公司 | 试剂盒及其制作方法 |
CN105567867A (zh) * | 2014-10-11 | 2016-05-11 | 上海仁度生物科技有限公司 | 人类免疫缺陷病毒1型实时荧光核酸恒温扩增检测试剂盒 |
CN104711370A (zh) * | 2015-01-09 | 2015-06-17 | 湖南圣湘生物科技有限公司 | 一种埃博拉病毒分型荧光pcr检测试剂盒 |
CN104846116A (zh) * | 2015-04-14 | 2015-08-19 | 广州海力特生物科技有限公司 | 检测人类免疫缺陷病毒1型的pcr引物组、探针及其试剂盒和检测方法 |
CN106119413A (zh) * | 2016-07-01 | 2016-11-16 | 浙江省疾病预防控制中心 | 一种艾滋病病毒多重荧光pcr检测试剂盒及检测方法 |
CN107090521A (zh) * | 2017-05-09 | 2017-08-25 | 广州海力特生物科技有限公司 | 一种人类免疫缺陷病毒ⅰ型总核酸hiv‑1 tna的试剂盒及其应用 |
CN107523648A (zh) * | 2017-07-26 | 2017-12-29 | 李桂秋 | 一种人类免疫缺陷病毒核酸定量检测试剂盒 |
CN107326102A (zh) * | 2017-08-01 | 2017-11-07 | 广西中医药大学附属瑞康医院(广西中西医结合医院) | 一种艾滋病试剂盒 |
CN108998570A (zh) * | 2018-08-14 | 2018-12-14 | 首都医科大学附属北京佑安医院 | 可覆盖多亚型的hiv-1总dna定量检测引物对、探针及检测试剂盒 |
CN108998570B (zh) * | 2018-08-14 | 2021-11-02 | 首都医科大学附属北京佑安医院 | 可覆盖多亚型的hiv-1总dna定量检测引物对、探针及检测试剂盒 |
CN109136395A (zh) * | 2018-08-27 | 2019-01-04 | 郑州安图生物工程股份有限公司 | 一种b族链球菌核酸检测试剂盒 |
CN109777891A (zh) * | 2019-03-19 | 2019-05-21 | 上海邦耀生物科技有限公司 | 一种检测gag基因的引物对和荧光探针的组合和检测方法 |
Also Published As
Publication number | Publication date |
---|---|
CN103074446B (zh) | 2014-04-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN103074446B (zh) | 一种人类免疫缺陷病毒核酸检测试剂盒 | |
Jurriaans et al. | The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? | |
Curtis et al. | Rapid detection of HIV-1 by reverse-transcription, loop-mediated isothermal amplification (RT-LAMP) | |
Van Gemen et al. | Quantification of HIV-1 RNA in plasma using NASBATM during HIV-1 primary infection | |
Semple et al. | Direct measurement of viraemia in patients infected with HIV‐1 and its relationship to disease progression and zidovudine therapy | |
US8575324B2 (en) | Methods and reagents for molecular detection of HIV-1 groups M, N and O | |
Stieger et al. | Competitive polymerase chain reaction assay for quantitation of HIV-1 DNA and RNA | |
CN109196124A (zh) | 同时检测及定量分析四种血源性病毒的多重Taqman探针qPCR的试剂盒及方法 | |
CN111286557A (zh) | 一种检测输血性传播病原体的试剂组合、试剂盒及应用 | |
Plantier et al. | Plasma RNA quantification and HIV-1 divergent strains | |
CN103045756A (zh) | 一种荧光定量rt-pcr检测人类免疫缺陷病毒1型的试剂盒 | |
CN104911277B (zh) | 一种检测干血斑标本中人类免疫缺陷病毒1型的试剂盒及其检测方法 | |
CN108998570B (zh) | 可覆盖多亚型的hiv-1总dna定量检测引物对、探针及检测试剂盒 | |
Olah et al. | Neither molecular diversity of the envelope, immunosuppression status, nor proviral load causes indeterminate HTLV western blot profiles in samples from human T‐cell lymphotropic virus type 2 (HTLV‐2)‐infected individuals | |
Kondo et al. | Quantitation of HIV-1 group M proviral DNA using TaqMan MGB real-time PCR | |
Cunningham et al. | False negative HIV-1 proviral DNA polymerase chain reaction in a patient with primary infection acquired in Thailand | |
Holodniy | Clinical application of reverse transcription-polymerase chain reaction for HIV infection | |
JP3351773B2 (ja) | Hiv−1のサブタイプ決定法 | |
CN105567867A (zh) | 人类免疫缺陷病毒1型实时荧光核酸恒温扩增检测试剂盒 | |
CN104212919B (zh) | 一种用于检测hiv-1病毒的lamp引物组合物及其应用 | |
CN113234853B (zh) | 同时检测hiv-1、hbv、hcv、cmv的特异性引物和试剂盒 | |
CN109371169B (zh) | 一种用于辅助诊断早期hiv感染的试剂盒及其专用成套引物对 | |
CN117821666A (zh) | 用于检测hiv-1的引物组及其应用和检测方法 | |
KR102141369B1 (ko) | 중증열성혈소판감소증후군 바이러스 유전자 검출용 조성물 및 이를 이용한 중증열성혈소판감소증후군의 진단방법 | |
Udeze et al. | Phylogeny of partial gag, pol and env genes show predominance of HIV-1G and CRF02_AG with emerging recombinants in south-eastern Nigeria |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
C14 | Grant of patent or utility model | ||
GR01 | Patent grant | ||
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Effective date: 20141120 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20141120 Address after: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee after: Hunan company limited of Sheng Weier medical test institute Address before: 410012 No. 198 west slope, Tongzi hi tech Industrial Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
ASS | Succession or assignment of patent right |
Owner name: HUNAN SHENGXIANG BIOLOGICAL TECHNOLOGY CO., LTD. Free format text: FORMER OWNER: HUNAN SHENGWEIER MEDICAL INSPECTION CO., LTD. Effective date: 20150723 |
|
C41 | Transfer of patent application or patent right or utility model | ||
TR01 | Transfer of patent right |
Effective date of registration: 20150723 Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Sansure Biotech Inc. Address before: 410012, No. 680, Lu Song Road, Changsha hi tech Development Zone, Hunan Patentee before: Hunan company limited of Sheng Weier medical test institute |
|
PE01 | Entry into force of the registration of the contract for pledge of patent right | ||
PE01 | Entry into force of the registration of the contract for pledge of patent right |
Denomination of invention: Human immunodeficiency virus (HIV) nucleic acid detection kit Effective date of registration: 20170711 Granted publication date: 20140409 Pledgee: Ningbo free trade zone Terry with equity investment partnership (limited partnership)|Suzhou equity equity investment center (limited partnership)|Ningbo Meishan Bonded Port District, Jun and equity investment partnership (limited partnership)|Chen Bang Pledgor: Hunan Gene Technology Co.|Hunan San Xiang Biological Technology Co. Ltd. Registration number: 2017430000042 |
|
CP01 | Change in the name or title of a patent holder | ||
CP01 | Change in the name or title of a patent holder |
Address after: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee after: Shengxiang Biotechnology Co., Ltd Address before: 410012, No. 680, Lu Song Road, hi tech Development Zone, Hunan, Changsha Patentee before: Sansure Biotech Inc. |
|
PC01 | Cancellation of the registration of the contract for pledge of patent right |
Date of cancellation: 20200217 Granted publication date: 20140409 Pledgee: Suzhou Lirui equity investment center (limited partnership)|Triton equity investment partnership (limited partnership)|JUNHE Tongrui equity investment partnership (limited partnership)|Chenbang Pledgor: SANSURE BIOTECH Inc. Registration number: 2017430000042 |